US Biosimilars See A Banner Year Despite Few Approvals
Multiple Products Compete On Key Molecules As Insulins Make Transition
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.
